CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Drug Metabolism

Background:

• Pharmacogenetic variants influence drug efficacy and safety through pharmacodynamic and pharmacokinetic alterations.
• Cytochrome P450 enzymes, particularly CYP2C19, play a key role in drug metabolism and have been central to precision medicine successes.
• CYP2C19 metabolizes the antiplatelet drug clopidogrel, a critical factor in cardiovascular disease management.

Purpose of the Study:

• To examine the clinical and scientific progress in implementing CYP2C19 genotyping for routine patient care.
• To highlight the impact of CYP2C19 genetic variations on clopidogrel therapy outcomes.
• To discuss the successes and challenges associated with advancing CYP2C19 genotyping.

Main Methods:

• Review of existing literature and clinical data on CYP2C19 polymorphisms and clopidogrel response.
• Analysis of outcomes in patients undergoing percutaneous coronary intervention treated with clopidogrel.
• Exploration of the integration of CYP2C19 genotyping into clinical practice.

Main Results:

• Loss-of-function CYP2C19 alleles are linked to a higher risk of coronary stent thrombosis and major adverse cardiovascular events in patients on clopidogrel.
• CYP2C19 genetic status significantly impacts the effectiveness and safety of clopidogrel therapy.
• Clinical implementation of CYP2C19 genotyping faces both advancements and obstacles.

Conclusions:

• CYP2C19 genotyping is essential for optimizing clopidogrel therapy and mitigating cardiovascular risks.
• Personalized antiplatelet treatment based on CYP2C19 genotype can improve patient outcomes.
• Continued efforts are needed to overcome challenges in the widespread clinical adoption of CYP2C19 genotyping.